Dianthus Therapeutics Inc. (DNTH) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Dianthus Therapeutics Inc...

    NASDAQ: DNTH · Real-Time Price · USD
    34.94
    -1.99 (-5.39%)
    At close: Oct 03, 2025, 3:59 PM
    34.00
    -2.69%
    After-hours: Oct 03, 2025, 06:26 PM EDT

    Dianthus Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 6.24M 2.83M 6.42M 1.48M
    Cost of Revenue
    		 n/a 355K 147K 2.02M
    Gross Profit
    		 6.24M 2.83M 6.27M -544K
    Operating Income
    		 -101.86M -48.17M -29.7M -74.69M
    Interest Income
    		 17.36M 4.76M 1.15M 100K
    Pretax Income
    		 -84.97M -43.55M -28.48M -13.11M
    Net Income
    		 -84.97M -43.55M -28.48M -13.11M
    Selling & General & Admin
    		 24.99M 18.16M 6.74M 1.96M
    Research & Development
    		 83.11M 32.84M 29.38M 12.61M
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 108.1M 51M 36.12M 14.56M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 108.1M 51M 36.12M 14.56M
    Income Tax Expense
    		 n/a n/a n/a n/a
    Shares Outstanding (Basic)
    		 33.31M 5.15M 3.75M 3.43M
    Shares Outstanding (Diluted)
    		 33.31M 5.15M 3.75M 3.43M
    EPS (Basic)
    		 -2.55 -8.45 -7.6 -3.82
    EPS (Diluted)
    		 -2.55 -8.45 -7.6 -3.82
    EBITDA
    		 -101.45M -47.82M -29.56M -69.12M
    EBIT
    		 -101.86M -48.17M -29.7M -71.14M
    Depreciation & Amortization
    		 412K 355K 147K 2.02M

    Add to Watchlist